CCBIO Research School course on Cancer Genomics
We are happy to introduce a brand new CCBIO Research School course: CCBIO906 - Cancer Genomics, which will take place November 1-3 2017!
Main content
This course will provide broad understanding of aspects of cancer genome biology and their investigation by next generation sequencing (NGS) technologies. Methods for analysing DNA variation and structure and RNA expression patterns will be covered, as well as nuclear and chromatin structure. Also ethical, legal aspects, and hereditary predisposition will be taught.
The course is recommended as part of the training component for all candidates affiliated with the Research School for Cancer Studies (RSCS).
Registration deadline is October 2nd. Please use this registration link.
Program
You can find the program on this link.
Learning outcomes
Upon completing this course the candidate should have knowledge regarding:
What kinds of mutations may predispose for, contribute to, or appear during cancer development
How these variants can be detected by NGS methods and be analysed bioinformatically
How to employ these methods to stratify patients both diagnostically and therapeutically
The different implications of the same aberrations depending on tissue type
Ethical and legal regulations regarding genetic analyses of patient samples
What skills you will learn
You will be able to formulate problems, plan and carry out NGS analyses on samples from cancer patients. You will also be able to assess the expediency and application of different NGS methods in cancer diagnostics and research, and to know the contact points for NGS analysis and data storage and analysis in the Bergen area. You will have knowledge about relevant literature and methods concerning cancer genomics.
General Competency
When completing the course, the candidate should be able to evaluate how knowledge about genome aberrations can help in understanding tumor biological mechanisms and as a guide to improved diagnosis, targeted treatment and follow up of cancer patients.